Therapeutic effects of flurbiprofen axetil on mesenteric traction syndrome: randomized clinical trial

Hidemasa Takahashi, Dai Shida, Kyoko Tagawa, Ryo Iwamoto, Makoto Arita, Hiroyuki Arai, Takeo Suzuki

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND: This study aimed to reveal the appropriate timing for the intravenous administration of flurbiprofen axetil for preventing mesenteric traction syndrome (MTS), caused by prostacyclin release.

METHODS: In this prospective, randomized, clinical study, forty-five patients who were undergoing elective surgery for colorectal cancer via laparotomy were enrolled. Patients were randomly divided into 3 groups: a preoperative group (n = 16) receiving flurbiprofen axetil directly before surgery; a post-MTS group (n = 14) receiving following MTS onset; and a control group (n = 15) who were not administered flurbiprofen axetil. 6-keto-PGF1α, a stable metabolite of prostacyclin, levels were measured and mean blood pressures were recorded.

RESULTS: In the preoperative group, 6-keto-PGF1α levels did not increase, blood pressure levels did not decrease, and no facial flushing was observed. In both the post-MTS and control groups, 6-keto-PGF1α levels increased markedly after mesenteric traction and blood pressure decreased significantly. The post-MTS group exhibited a faster decreasing trend in 6-keto-PGF1α levels and quick restore of the mean blood pressure, and the use of vasopressors and phenylephrine were lower than that in the control group.

CONCLUSIONS: Even therapeutic administration of flurbiprofen axetil after the onset of MTS has also effects on MTS by suppressing prostacyclin production.

TRIAL REGISTRATION: Clinical trial number: UMIN000009111 . (Registered 14 October 2012).

Original languageEnglish
Number of pages1
JournalBMC Surgery
Volume17
Issue number1
DOIs
Publication statusPublished - 2017 Aug 11
Externally publishedYes

Fingerprint

Traction
Therapeutic Uses
Randomized Controlled Trials
Epoprostenol
Blood Pressure
Control Groups
flurbiprofen axetil
Phenylephrine
Intravenous Administration
Laparotomy
Colorectal Neoplasms
Clinical Trials
prostaglandin F1

Keywords

  • 6-keto-prostaglandin F1α
  • Colorectal cancer
  • Flurbiprofen axetil
  • Mesenteric traction syndrome
  • Prostacyclin

ASJC Scopus subject areas

  • Surgery

Cite this

Therapeutic effects of flurbiprofen axetil on mesenteric traction syndrome : randomized clinical trial. / Takahashi, Hidemasa; Shida, Dai; Tagawa, Kyoko; Iwamoto, Ryo; Arita, Makoto; Arai, Hiroyuki; Suzuki, Takeo.

In: BMC Surgery, Vol. 17, No. 1, 11.08.2017.

Research output: Contribution to journalArticle

Takahashi, Hidemasa ; Shida, Dai ; Tagawa, Kyoko ; Iwamoto, Ryo ; Arita, Makoto ; Arai, Hiroyuki ; Suzuki, Takeo. / Therapeutic effects of flurbiprofen axetil on mesenteric traction syndrome : randomized clinical trial. In: BMC Surgery. 2017 ; Vol. 17, No. 1.
@article{9dab61999a6645dfaf61f5ba51c43366,
title = "Therapeutic effects of flurbiprofen axetil on mesenteric traction syndrome: randomized clinical trial",
abstract = "BACKGROUND: This study aimed to reveal the appropriate timing for the intravenous administration of flurbiprofen axetil for preventing mesenteric traction syndrome (MTS), caused by prostacyclin release.METHODS: In this prospective, randomized, clinical study, forty-five patients who were undergoing elective surgery for colorectal cancer via laparotomy were enrolled. Patients were randomly divided into 3 groups: a preoperative group (n = 16) receiving flurbiprofen axetil directly before surgery; a post-MTS group (n = 14) receiving following MTS onset; and a control group (n = 15) who were not administered flurbiprofen axetil. 6-keto-PGF1α, a stable metabolite of prostacyclin, levels were measured and mean blood pressures were recorded.RESULTS: In the preoperative group, 6-keto-PGF1α levels did not increase, blood pressure levels did not decrease, and no facial flushing was observed. In both the post-MTS and control groups, 6-keto-PGF1α levels increased markedly after mesenteric traction and blood pressure decreased significantly. The post-MTS group exhibited a faster decreasing trend in 6-keto-PGF1α levels and quick restore of the mean blood pressure, and the use of vasopressors and phenylephrine were lower than that in the control group.CONCLUSIONS: Even therapeutic administration of flurbiprofen axetil after the onset of MTS has also effects on MTS by suppressing prostacyclin production.TRIAL REGISTRATION: Clinical trial number: UMIN000009111 . (Registered 14 October 2012).",
keywords = "6-keto-prostaglandin F1α, Colorectal cancer, Flurbiprofen axetil, Mesenteric traction syndrome, Prostacyclin",
author = "Hidemasa Takahashi and Dai Shida and Kyoko Tagawa and Ryo Iwamoto and Makoto Arita and Hiroyuki Arai and Takeo Suzuki",
year = "2017",
month = "8",
day = "11",
doi = "10.1186/s12893-017-0286-y",
language = "English",
volume = "17",
journal = "BMC Surgery",
issn = "1471-2482",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Therapeutic effects of flurbiprofen axetil on mesenteric traction syndrome

T2 - randomized clinical trial

AU - Takahashi, Hidemasa

AU - Shida, Dai

AU - Tagawa, Kyoko

AU - Iwamoto, Ryo

AU - Arita, Makoto

AU - Arai, Hiroyuki

AU - Suzuki, Takeo

PY - 2017/8/11

Y1 - 2017/8/11

N2 - BACKGROUND: This study aimed to reveal the appropriate timing for the intravenous administration of flurbiprofen axetil for preventing mesenteric traction syndrome (MTS), caused by prostacyclin release.METHODS: In this prospective, randomized, clinical study, forty-five patients who were undergoing elective surgery for colorectal cancer via laparotomy were enrolled. Patients were randomly divided into 3 groups: a preoperative group (n = 16) receiving flurbiprofen axetil directly before surgery; a post-MTS group (n = 14) receiving following MTS onset; and a control group (n = 15) who were not administered flurbiprofen axetil. 6-keto-PGF1α, a stable metabolite of prostacyclin, levels were measured and mean blood pressures were recorded.RESULTS: In the preoperative group, 6-keto-PGF1α levels did not increase, blood pressure levels did not decrease, and no facial flushing was observed. In both the post-MTS and control groups, 6-keto-PGF1α levels increased markedly after mesenteric traction and blood pressure decreased significantly. The post-MTS group exhibited a faster decreasing trend in 6-keto-PGF1α levels and quick restore of the mean blood pressure, and the use of vasopressors and phenylephrine were lower than that in the control group.CONCLUSIONS: Even therapeutic administration of flurbiprofen axetil after the onset of MTS has also effects on MTS by suppressing prostacyclin production.TRIAL REGISTRATION: Clinical trial number: UMIN000009111 . (Registered 14 October 2012).

AB - BACKGROUND: This study aimed to reveal the appropriate timing for the intravenous administration of flurbiprofen axetil for preventing mesenteric traction syndrome (MTS), caused by prostacyclin release.METHODS: In this prospective, randomized, clinical study, forty-five patients who were undergoing elective surgery for colorectal cancer via laparotomy were enrolled. Patients were randomly divided into 3 groups: a preoperative group (n = 16) receiving flurbiprofen axetil directly before surgery; a post-MTS group (n = 14) receiving following MTS onset; and a control group (n = 15) who were not administered flurbiprofen axetil. 6-keto-PGF1α, a stable metabolite of prostacyclin, levels were measured and mean blood pressures were recorded.RESULTS: In the preoperative group, 6-keto-PGF1α levels did not increase, blood pressure levels did not decrease, and no facial flushing was observed. In both the post-MTS and control groups, 6-keto-PGF1α levels increased markedly after mesenteric traction and blood pressure decreased significantly. The post-MTS group exhibited a faster decreasing trend in 6-keto-PGF1α levels and quick restore of the mean blood pressure, and the use of vasopressors and phenylephrine were lower than that in the control group.CONCLUSIONS: Even therapeutic administration of flurbiprofen axetil after the onset of MTS has also effects on MTS by suppressing prostacyclin production.TRIAL REGISTRATION: Clinical trial number: UMIN000009111 . (Registered 14 October 2012).

KW - 6-keto-prostaglandin F1α

KW - Colorectal cancer

KW - Flurbiprofen axetil

KW - Mesenteric traction syndrome

KW - Prostacyclin

UR - http://www.scopus.com/inward/record.url?scp=85044172245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044172245&partnerID=8YFLogxK

U2 - 10.1186/s12893-017-0286-y

DO - 10.1186/s12893-017-0286-y

M3 - Article

C2 - 28800765

AN - SCOPUS:85044172245

VL - 17

JO - BMC Surgery

JF - BMC Surgery

SN - 1471-2482

IS - 1

ER -